CYP3A5 Polymorphism in Circulating Tumor Cells Confers an Increased Disease-Free Survival in DLBCL Patients Treated with R-CHOP

    March 2025 in “ OncoTargets and Therapy ”
    Rafael Cerón Maldonado, Adolfo Martínez Tovar, Christian Omar Ramos Peñafiel, Adrián De la Cruz Rosas, Anel Irais García Laguna, Iveth Mendoza Salas, Carlos Martínez‐Murillo, Gilberto Barranco-Lampón, Efreen Horacio Montaño Figueroa, Silvia Jiménez‐Morales, Irma Olarte‐Carrillo
    Image
    Studysummary This study found that in circulating tumor cells from non-invasive liquid biopsies, the GG genotype of the CYP3A5 A6986G affects longer disease-free survival in DLBCL patients, highlighting the significance of circulating biomarkers for prognostic evaluation.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study found that the GG genotype in the CYP3A5 A6986G polymorphism, present in circulating tumor cells (CTCs) from liquid biopsies, is associated with longer disease-free survival (DFS) in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. This highlights the importance of circulating biomarkers in non-invasive samples for improving DLBCL prognosis.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results